Table 4.
Simulated Percentage of Subjects Assuming Phase 3 Sample Size Who Achieve Different Efficacy End Points (NRI) in Week 16
| Dose Group | Placebo | 7.5 mg Once Daily | 15 mg Once Daily | 30 mg Once Daily |
|---|---|---|---|---|
| EASI‐75 | 9 (3‐17) | 32 (22‐40) | 48 (36‐60) | 68 (54‐81) |
| [10] | [29] | [52] | [69] | |
| EASI‐90 | 2 (0‐10) | 14 (10‐23) | 26 (17‐36) | 48 (31‐62) |
| [2] | [14] | [26] | [50] | |
| IGA 0/1 | 2 (0‐11) | 17 (10‐27) | 29 (19‐40) | 49 (31‐63) |
| [2] | [14] | [31] | [50] |
Note: Results represent median percentage of subjects (5th and 95th percentiles) from 200 replicates with 270 subjects/dose group in each replicate [observed percentage of subjects].